| 1404 |
National Cancer Institute |
Html |
en |
Sleep Disorders (PDQ®)–Patient Version |
Expert-reviewed information summary about causes and management of sleep disorders in people with cancer. |
| normal sleep patterns | 0.734479 |
| Relaxation therapy | 0.493159 |
| moderate sleep disorders | 0.656166 |
| sleeping problems | 0.484122 |
| PDQ cancer information | 0.646663 |
| sleep medicines | 0.601935 |
| health care team | 0.479673 |
| clinical trials | 0.518721 |
| sleep history | 0.612308 |
| sleep apnea | 0.593611 |
| cancer patient sleeps | 0.499804 |
| cancer information summary | 0.579061 |
| clinical trial | 0.483994 |
| breast cancer prevention | 0.483786 |
| good sleep habits | 0.703452 |
| cancer patients | 0.541537 |
| treatment instructions | 0.483188 |
| sleep problems | 0.627478 |
| mild sleep disorders | 0.656367 |
| NCI’s PDQ | 0.480637 |
| NCI PDQ cancer | 0.525102 |
| Common cancer treatments | 0.495476 |
| sleep disorder clinic | 0.627008 |
| deep sleep | 0.635758 |
|
| treatment | 0.54776 |
| cancer prevention | 0.48441 |
| lighter sleep | 0.598128 |
| Cancer Information Service | 0.493437 |
| REM sleep | 0.662129 |
| sleep | 0.949433 |
| good night | 0.507447 |
| National Cancer Institute | 0.585654 |
| sleep repeat | 0.634943 |
| light sleep | 0.635787 |
| Palliative Care Editorial | 0.524141 |
| new treatment | 0.481731 |
| sleep disorders | 0.849206 |
| sleep restriction | 0.605553 |
| Cancer Care page | 0.486706 |
| Care Editorial Board | 0.525467 |
| health | 0.498616 |
| PDQ summary | 0.533115 |
| sleep disorder | 0.712776 |
| sleep problem | 0.601447 |
| cancer information summaries | 0.498019 |
| comprehensive cancer information | 0.497854 |
| cancer | 0.67715 |
| stimulus control | 0.540953 |
|
CLICK HERE |
| 1931 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de ovario de bajo potencial maligno (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de ovario de bajo potencial maligno. |
| potencial maligno recidivantes | 0.922565 |
| siguientes procedimientos | 0.427427 |
| tarde.ampliar ecografÃa abdominal | 0.259992 |
| estadio iv | 0.702134 |
| estadio tardÃo quizás | 0.295045 |
| siguientes aspectos | 0.213133 |
| rayos x | 0.188575 |
| estadio ic | 0.522053 |
| estadio ib | 0.526427 |
| estadio ia | 0.52265 |
| National Cancer Institute | 0.172435 |
| siguientes riesgos | 0.159887 |
| tratamiento quizás | 0.234452 |
| Instituto Nacional | 0.353292 |
| áreas anormales.ampliar examen | 0.232843 |
|
| estadio iiia | 0.49525 |
| PDQ Tratamiento | 0.250127 |
| estadio iiic | 0.497145 |
| estadio iiib | 0.498374 |
| estadio iia | 0.510853 |
| estadio iib | 0.521745 |
| estadio iic | 0.517926 |
| Physician Data Query | 0.359777 |
| potencial maligno causa | 0.737758 |
| maligno causa efectos | 0.613505 |
| siguientes enlaces | 0.168488 |
| ecografÃa transvaginal.Ampliar | 0.196606 |
| histerectomÃa abdominal | 0.202556 |
| siguientes pruebas | 0.233116 |
|
CLICK HERE |
| 1996 |
National Cancer Institute |
Html |
es |
Comunicación en la atención del cáncer (PDQ®)–Versión para pacientes |
Resumen de la información revisada por expertos acerca de la comunicación con el paciente de cáncer y sus familiares, que incluye los aspectos distintivos de la comunicación con pacientes de cáncer, los factores que afectan la comunicación y la capacitación en aptitudes para la comunicación. |
| comunicación mejora | 0.843776 |
| familia ayuda | 0.776248 |
| siguientes casos | 0.791497 |
| Physician Data Query | 0.942554 |
| mejores decisiones | 0.835028 |
| siguientes preguntas | 0.768644 |
| suministra información | 0.764377 |
| salud ayuda | 0.830465 |
| médico ayuda | 0.964949 |
|
| National Cancer Institute | 0.757167 |
| siguientes indicaciones | 0.779865 |
| ¿Cuáles archivos | 0.761738 |
| siguientes riesgos | 0.741613 |
| PDQ Comunicación | 0.825783 |
| comunicación ayuda | 0.895884 |
| Instituto Nacional | 0.809598 |
| ¿Cuáles problemas | 0.755893 |
|
CLICK HERE |
| 2076 |
National Cancer Institute |
Html |
es |
Alcohol y el riesgo de cáncer |
Hoja informativa que resume la comprobación de la relación entre el consumo de alcohol y el riesgo de varios cánceres. Incluye información de los factores que afectan el riesgo de cánceres asociados con el alcohol, como son los genes y el uso de tabaco. |
| Neck Cancer Epidemiology | 0.538614 |
| Lancet Oncology | 0.534891 |
| Hirose K | 0.511352 |
| Matsuo K | 0.510531 |
| levadura fermenta azúcares | 0.523222 |
| pharyngeal cancers | 0.510877 |
| Alcohol drinking cessation | 0.626157 |
| British Journal | 0.511017 |
| vitamina a | 0.51094 |
| Straif K | 0.510855 |
| vitamina e | 0.511443 |
| IARC Monographs | 0.512402 |
| IARC Working Group | 0.518509 |
| riesgos resultantes | 0.517271 |
| Estados Unidos | 0.591854 |
| alcohol drinking | 0.759868 |
| Tajima K | 0.511125 |
| PubMed Abstract | 0.957874 |
| neck cancers | 0.610459 |
| Cancer Epidemiology | 0.551257 |
| Beral V | 0.510723 |
| Liver Disease | 0.511887 |
| cancer prevention | 0.54975 |
| alcohol consumption with | 0.621668 |
| vino tinto | 0.531211 |
|
| results from subgroup | 0.518268 |
| International Head | 0.510721 |
| Fedirko V | 0.510662 |
| contaminantes cancerÃgenos | 0.510849 |
| Carcinogenic Risks | 0.530612 |
| ADH hiperactiva | 0.535244 |
| Numerosos estudios | 0.516257 |
| preclinical studies | 0.511192 |
| enzima hiperactiva | 0.522144 |
| Bonifazi M | 0.510536 |
| epidemiological studies | 0.512501 |
| Hodgkin lymphoma | 0.511109 |
| enzima adh hiperactiva | 0.532963 |
| Tramacere I | 0.552596 |
| genetic polymorphisms | 0.530043 |
| enzima llamada | 0.519065 |
| Bagnardi V | 0.51066 |
| Rehm J | 0.529488 |
| cabo estudios | 0.515059 |
| pooled analysis | 0.527827 |
| renal cell carcinoma | 0.521274 |
| Cancer Institute | 0.525901 |
| células renales | 0.53114 |
| New York Academy | 0.514614 |
|
CLICK HERE |
| 2106 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de endometrio (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de endometrio. |
| PDQ Tratamiento | 0.669269 |
| general causa sÃntomas | 0.588555 |
| Visuals Online | 0.525614 |
| PDQ Exámenes | 0.596864 |
| cáncer.Los exámenes | 0.641713 |
| Physician Data Query | 0.681868 |
| pequeña cantidad | 0.54391 |
| Estados Unidos | 0.562116 |
| cuello uterino | 0.811632 |
|
| prevención revisa | 0.531482 |
| ecografÃa endovaginal | 0.56717 |
| información ayuda | 0.538498 |
| National Cancer Institute | 0.545187 |
| ecografÃa transvaginal | 0.942856 |
| siguientes riesgos | 0.532576 |
| siguientes sumarios | 0.618993 |
| Instituto Nacional | 0.58569 |
|
CLICK HERE |
| 3527 |
National Cancer Institute |
Html |
es |
Cáncer de próstata, nutrición y suplementos alimentarios (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de la nutrición y los suplementos alimentarios para disminuir el riesgo de presentar cáncer de próstata o como tratamiento del mismo. |
| World Cancer Research | 0.326698 |
| Cancer Research Fund | 0.313691 |
| Causes Control | 0.305123 |
| Sin embargo | 0.321932 |
| accessed october | 0.306323 |
| productos lácteos | 0.431605 |
| vitamina d | 0.31442 |
| ayunas polyphenon | 0.305303 |
| Preventive Services Task | 0.311029 |
| vitamina e | 0.30874 |
| Instituto Nacional | 0.305332 |
| GEGC Estado Duración | 0.307099 |
| ratones tramp | 0.382139 |
| among men with | 0.325726 |
| Estados Unidos | 0.340412 |
| Natl Cancer Inst | 0.313037 |
| Ayunas Dosis | 0.305586 |
| PDQ Prevención | 0.307 |
| men with | 0.346832 |
| systematic evidence review | 0.313097 |
| prostate tumor | 0.309841 |
| cohort studies | 0.305885 |
| Cancer Prostate Sweden | 0.316805 |
| cohort study | 0.307709 |
| Boon H | 0.305432 |
|
| vitamin d | 0.306351 |
| dietary calcium | 0.324651 |
| diagnosed with | 0.308047 |
| Prostate CAncer Therapy | 0.319442 |
| Nutr Cancer | 0.324876 |
| as risk factors | 0.306238 |
| alto consumo | 0.312193 |
| Cancer Research | 0.341162 |
| Cancer Care | 0.312902 |
| Epidemiol Biomarkers Prev | 0.355426 |
| Mitrou PN | 0.306395 |
| Clin Nutr | 0.308257 |
| subsequent risk | 0.305051 |
| estudio pcats | 0.30523 |
| Services Task Force | 0.310689 |
| principales fuentes | 0.3052 |
| systematic review | 0.306566 |
| risk factor | 0.3097 |
| Dietary calcium does | 0.306286 |
| prostate cancer | 0.981425 |
| Albanes D | 0.30581 |
| Polyphenon E | 0.333052 |
| risk with specific | 0.307113 |
| dairy products | 0.430021 |
|
CLICK HERE |
| 15641 |
National Cancer Institute |
Html |
en |
Research Performance Progress Report (RPPR) |
Find more information about the RPPR, which documents recipient accomplishments and compliance with terms of award. |
| non-competing renewal | 0.483928 |
| public access policy | 0.676757 |
| NCI program | 0.46997 |
| business official | 0.461707 |
| grants management specialist | 0.511753 |
| Institutional Review Board | 0.501375 |
| recipient accomplishments | 0.470927 |
| progress reports | 0.710572 |
| budget period | 0.703772 |
| Performance Progress Report | 0.705145 |
| competing project period | 0.527715 |
| NCBI | 0.472549 |
| NIH staff | 0.493692 |
| Type 4s | 0.462417 |
| additional information | 0.516454 |
| email notification reminders | 0.504215 |
| award progress reports | 0.597891 |
| PubMed Central ID | 0.510154 |
| budget periods | 0.468611 |
| Progress Report Additional | 0.614182 |
| multiple PIs | 0.466396 |
| contact PI | 0.464615 |
| award process | 0.523874 |
| Management staff review | 0.506533 |
| final peer-reviewed journal | 0.498525 |
|
| grants management staff | 0.612225 |
| additional information online | 0.514579 |
| recipient wishes | 0.463817 |
| different schedule | 0.465588 |
| Institutional Animal Care | 0.498988 |
| annual progress reports | 0.586399 |
| progress report | 0.93768 |
| scientific progress | 0.590143 |
| subsequent budget period | 0.638937 |
| final progress report | 0.600792 |
| NIH applications | 0.499628 |
| eRA Commons | 0.829812 |
| full-text papers | 0.492864 |
| Non-competing continuation | 0.468466 |
| NCI staff | 0.465398 |
| Streamlined Noncompeting Award | 0.520709 |
| NIH funds | 0.496167 |
| NIH Public Access | 0.629563 |
| RPPR | 0.513098 |
| NIH funding | 0.492377 |
| Research Performance Progress | 0.694309 |
| Business Technology Transfer | 0.507309 |
| incomplete applications | 0.461976 |
| Small Business | 0.499434 |
|
CLICK HERE |
| 16826 |
National Cancer Institute |
Html |
en |
Early Onset Malignancies Initiative |
The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations. |
| community sites | 0.48513 |
| control group | 0.496806 |
| certain minority populations | 0.77365 |
| exome sequencing | 0.513318 |
| ethnic populations | 0.59564 |
| ethnic groups | 0.477288 |
| multiple platforms | 0.483426 |
| early detection | 0.483135 |
| tumor behavior | 0.507221 |
| cutting-edge genomic characterization | 0.794697 |
| early age | 0.515521 |
| genomic datasets | 0.554094 |
| patient populations | 0.708455 |
| multiple myeloma | 0.479782 |
| critical research | 0.469762 |
| rich genomic data | 0.741156 |
| cancer types | 0.666255 |
| Thorough clinical data | 0.657553 |
| extensive data | 0.513023 |
| clinical measures | 0.479008 |
| molecular targets | 0.47719 |
| TCGA | 0.415616 |
| tumor progression | 0.525349 |
| earlier age | 0.508182 |
|
| higher rates | 0.504515 |
| important insights | 0.491579 |
| molecular drivers | 0.46961 |
| cancer type | 0.492461 |
| NCI Genome Characterization | 0.808398 |
| early disease | 0.497354 |
| clinical updates | 0.489197 |
| disease monitoring | 0.476658 |
| Genome Characterization Pipeline | 0.932301 |
| collaborative initiative | 0.505734 |
| NCI genomic characterization | 0.824673 |
| EOMI | 0.680345 |
| NCI Community Oncology | 0.754977 |
| total RNA sequencing | 0.668278 |
| underrepresented minorities | 0.53639 |
| Cancer Genome Atlas | 0.669216 |
| tissue samples | 0.659999 |
| Early Onset Malignancies | 0.747146 |
| EOMI data | 0.528397 |
| treatment response | 0.492799 |
| cancer risk | 0.496991 |
| genome sequencing | 0.549082 |
| Cancer Prevention | 0.5334 |
| normal tissue samples | 0.654735 |
|
CLICK HERE |
| 17277 |
National Cancer Institute |
Html |
null |
Cáncer avanzado y quienes cuidan |
Si usted cuida a un paciente, puede sentir cansancio y preocupación a medida que se enfrenta al cáncer de su ser querido. Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas. |
|
|
CLICK HERE |
| 17288 |
National Cancer Institute |
Html |
es |
Personal de atención para la salud |
Información sobre el equipo de tratamiento de proveedores de salud que trabajan juntos para ayudar a pacientes con cáncer. |
| cuáles alimentos | 0.989407 |
|
|
CLICK HERE |